The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 14 June 2005, www.theannals.com, DOI 10.1345/aph.1E680.
 The Annals of Pharmacotherapy: Vol. 39, No. 7, pp. 1302-1308. DOI 10.1345/aph.1E680
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goedken, A. M
Right arrow Articles by Herman, R. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goedken, A. M
Right arrow Articles by Herman, R. A

HIV/AIDS

Once-Daily Abacavir in Place of Twice-Daily Administration

Amber M Goedken, PharmD

Drug Informatics Resident, Iowa Drug Information Network, Iowa City, IA

Ronald A Herman, PhD

Director, Iowa Drug Information Network; Associate Professor (Clinical), College of Pharmacy, University of Iowa, Iowa City

Reprints: Dr. Herman, Iowa Drug Information Network, 100 Oakdale Campus, N344 OH, Iowa City, IA 52242-5000, fax 319/335-4440, ronald-a-herman{at}uiowa.edu

OBJECTIVE: To review the safety and efficacy of a once-daily dosage regimen for abacavir, a nucleoside reverse transcriptase inhibitor.

DATA SOURCES: English-language MEDLINE and Iowa Drug Information Service database reports were accessed from 1966 to March 2005. International Pharmaceutical Abstracts was searched from 1970 to March 2005. The key words used in all searches were abacavir and Ziagen. Article bibliographies were used to identify additional relevant articles. The Internet was searched to identify abstracts of poster and oral presentations that have not yet been published. The manufacturer was also contacted to obtain unpublished information.

STUDY SELECTION AND DATA EXTRACTION: Publications were included that provided information related to the safety and efficacy of abacavir when used once daily. Preference was given to randomized, double-blind, controlled trials comparing once-daily abacavir regimens with other antiretroviral regimens. Abstracts from professional meetings were included for unpublished studies, and conference coverage reviews were included if the abstracts were not available.

DATA SYNTHESIS: In trials directly comparing once- and twice-daily abacavir, little difference was shown in the efficacy of the 2 regimens. Despite similar adverse effect profiles, significantly more severe hypersensitivity reactions and severe diarrhea were seen with once-daily abacavir in one trial.

CONCLUSIONS: Once-daily administration of abacavir has not been shown to be inferior to twice-daily dosing, but it may put patients at increased risk for severe hypersensitivity reactions and diarrhea. More data are needed to confirm this risk.

Key Words: abacavir, nucleoside reverse transcriptase inhibitor: dosing

Published Online, June 14, 2005. www.theannals.com, DOI 10.1345/aph.1E680


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
C. A Hughes, M. M Foisy, N. Dewhurst, N. Higgins, L. Robinson, D. V Kelly, and K. E Lechelt
Abacavir Hypersensitivity Reaction: an Update
Ann. Pharmacother., March 1, 2008; 42(3): 387 - 396.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.